Muhamed Baljevic MD

Hematologic Oncology

Physician

3601 21st Ave SNashville, TN 37232
Phone+1 615-322-3000
Fax+1 402-552-2512

Dr. Baljevic is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Baljevic's full profile Already have an account?

Education & Training

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2013 - 2016
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2010 - 2013
Weill Cornell Medical College in QatarClass of 2010

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

TN State Medical License 2021 - 2026
NE State Medical License 2016 - 2022
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2017
CMS Meaningful Use Stage 1 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2017

Publications & Presentations

PubMed

Long-term extended-interval teclistamab and talquetamab dosing without step-up dosing in previously treated multiple myeloma.
Callee Brooks, Leslie Mader, Kathryn Kennedy, Phyu Thin Naing, Salyka Sengsayadeth
Experimental Hematology & Oncology. 2026-08-12
Retreatment with talquetamab and pomalidomide in triple-class-BCMA-GPRC5D refractory myeloma.
Kian J Rahbari, Gliceida M Galarza Fortuna, Bhagirathbhai Dholaria, Douglas W Sborov, Muhamed Baljevic
British Journal of Haematology. 2026-07-01
Real-World Diagnostic Workup of Patients Suspected for Light Chain Amyloidosis and Wild-Type Transthyretin Amyloid Cardiomyopathy: A Retrospective Cohort Study Using U...
Muhamed Baljevic, Haechung Chung, Jose Alvir, Patrick Feron, Aaron Crowley
Ejhaem. 2026-06-01

Abstracts/Posters

Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
Muhamed Baljevic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
The Effect of Age and CD34+ Stem Cell Dose on Autologous Hematopoietic Stem Cell Transplantation Outcomes in Multiple Myeloma _ Single Institution Experience
Muhamed Baljevic, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Guide Published for Outpatient Cancer Treatment with Bispecific AntibodiesJanuary 12th, 2026
New Faculty Spotlight: Muhamed Baljevic, M.DNovember 14th, 2016